High levels of immune suppression are a common intrinsic mechanism of resistance in metastatic breast cancer that calls for developing immunotherapeutic combinations to broaden treatment responses. Histone deacetylase (HDAC) inhibitors can sensitize tumors to dual checkpoint inhibition in patients. Here, we investigated the tumor microenvironment (TME) of breast metastases by combining experimental and clinical data with theory to elucidate the mechanism of response to treatment with the HDAC inhibitor entinostat combined with anti–PD-1 and anti–CTLA-4. Knowledge-guided subclustering of single-cell RNA-sequencing (scRNA-seq) data and cell circuit analyses from murine breast-to-lung metastases identified 39 cell states and salient interactions, of which myeloid, T-cell, and B-cell subpopulations were most affected. Analyses of patient biopsy specimens and blood via spatial proteomics and flow cytometry corroborated the preclinical findings, showing increased T- and B-cell activation, mature tertiary lymphoid structures, and increased CD8+ T cell–macrophage distances in responders to entinostat + nivolumab + ipilimumab. Combination treatment increased immunoglobulin production in patients and mice, and murine studies demonstrated increased tumor-targeting IgG and implicated B cells as necessary for treatment response. Inhibition of the intercellular adhesion molecule 1 and IFNγ pathways in myeloid cells partially recapitulated treatment effects on CD8+ T cells observed via scRNA-seq. Mathematical modeling of tumor-immune dynamics implicated simultaneous modulation of multiple TME interactions as required for response to the combination treatment. Overall, this study identifies lymphoid and myeloid cell contributions to response to treatment with HDAC inhibitors and immune checkpoint blockade, providing a framework for discovering interactions driving responses in complex TMEs. Significance:Integrative data analysis and mathematical modeling reveal immune interactions that sensitize the metastatic tumor microenvironment to checkpoint inhibition, validating the potential of cancer systems immunology approaches to uncover mechanisms of immunotherapeutic response.See related commentary by Senent and Manguso, p. 5603